av Gerbrand Koster | mar 7, 2022
Business opportunity Monoclonal antibodies have revolutionized treatment, especially for cancer and autoimmune diseases. However, a full cure of disease is often not achieved. Most approved antibodies are of the IgG1 subclass, which has a long plasma half-life and...
av Aina Rengmark | nov 12, 2021
Business opportunity Scientists from Oslo University Hospital and University of Oslo observed that Vastiras (VAS), a cardiac hormone recombinant-peptide with known beneficial effects on the kidney, has therapeutic effects on the heart in two distinct animal models of...
av Mohammed Amarzguioui | nov 12, 2021
Scientists at Oslo University Hospital have developed an immunotoxin, MOC31PE, comprising a full-length murine antibody against the epithelial surface antigen EpCAM, which is frequently overexpressed in many cancer forms, coupled to Pseudomonas exotoxin A (PE). Under...
av Mika Falck-Hansen | okt 29, 2021
Business opportunity Solid tumours are a cause of significant morbidity and mortality. This technology has the possibility to effectively treat a wide variety of advanced stage, solid tumours...
av Eirik A. Torheim | jun 23, 2021
Our team at Oslo University Hospital and University of Oslo has developed a novel targeting sequence that allows for direct targeting of vaccine antigens to immune cells, thereby improving the immunogenicity and efficacy of subunit vaccines. While the technology can...
